What Клофранил Treats: Main Uses and Benefits

Клофранил is an established therapeutic agent commonly used to help manage complex neuropsychiatric symptom patterns, relevant in clinical settings marked by heightened patient distress and significant functional disruption. The application of this medication is relevant across domains involving heightened responses, especially Obsessive-Compulsive Disorder, with common application across various mood and anxiety states.

The medication is relevant for easing symptoms related to persistent, disruptive conditions such as Obsessive-Compulsive Disorder (OCD), Major Depressive Disorder, and anxiety syndromes marked by heightened symptoms, like recurrent panic attacks. It also plays a role in managing specific chronic, complex symptoms, including cataplexy associated with narcolepsy and certain types of neuropathic pain.

“Its use is focused on providing symptom stabilization, which may contribute to improved day-to-day comfort during symptomatic phases.”

This support helps address symptom clusters that may become intense or disruptive. It may assist with easing the overall symptom load, supporting general well-being, and helping patients cope more steadily with difficult episodes.

---

Quick Fact: Symptomatic support for Intrusive Thoughts and Compulsive Behaviors

Regulatory References

1. NIH NCBI Bookshelf overview of Clomipramine

Клофранил (Clomipramine) eligibility is strictly defined by regulatory documents, focusing on age, cardiac health, and specific pre-existing conditions.

Contraindicated Populations

Use is absolutely prohibited in patients with a history of recent myocardial infarction or existing cardiac disorders, including heart block or cardiac arrhythmias. The medicine must also not be given concurrently with, or within 14 days of stopping, a Monoamine Oxidase Inhibitor (MAOI). Severe liver disease and known hypersensitivity to clomipramine or other dibenzazepine-group antidepressants are also contraindications [SmPC].

Age and Physiological Restrictions

• Pediatric Use: The only established use is in children aged 10 years and older for Obsessive-Compulsive Disorder (OCD). Use in children under 10 years is not established, and it is not recommended for the treatment of depression or phobias in patients under 18 years [FDA Label].
• Older Adults: Patients over 65 years require caution as they may exhibit a stronger response and are more susceptible to adverse effects [SmPC].
• Pregnancy and Lactation: Use is not recommended during pregnancy and is generally advised against during lactation, as clomipramine passes into breast milk [SmPC].

Conditional Use

Клофранил must be administered with caution in patients with renal impairment, pre-existing liver conditions (if not severe), a history of seizures, or conditions like narrow-angle glaucoma [SmPC].

Interactions with other medicines and products

Official regulatory documentation details specific and stringent restrictions regarding the co-administration of Clomipramine Hydrochloride (Клофранил) with other substances, primarily categorized by pharmacokinetic and pharmacodynamic interactions.

---

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including the antibiotics Linezolid and Intravenous Methylene Blue, is formally contraindicated due to the severe risk of Serotonin Syndrome.

Timing separation is mandatory: Clomipramine should not be started until at least 14 days after stopping an MAOI. A minimum of 5 weeks should elapse between discontinuing strong long-acting serotonergic agents like Fluoxetine and initiating Clomipramine.

---

Pharmacokinetic and Pharmacodynamic Effects

Metabolic Inhibitors: Co-administration with strong inhibitors of the CYP2D6 enzyme (e.g., Fluoxetine, Paroxetine) or CYP1A2 (e.g., Fluvoxamine) results in officially documented increased plasma concentrations of Clomipramine and its active metabolite. Conversely, Hepatic Enzyme Inducers may reduce plasma levels.

Pharmacodynamic Interactions: Additive effects occur with other serotonergic agents (increasing Serotonin Syndrome risk) and with substances that depress the central nervous system, such as Alcohol or the herbal supplement St. John's Wort. Potentiation of effects is also noted with Sympathomimetic and Anticholinergic Agents.

Population Notes: Regulatory information indicates that plasma concentrations are significantly lower in smokers and potentially higher in elderly patients.

How Клофранил Works

The action of Clomipramine Hydrochloride is based on its dual impact on two main neurobiological systems: the reuptake of key chemical messengers and the direct blocking of various receptors.

---

Dual Monoamine Neurotransmitter Enhancement

The primary mechanism involves blockade of the Serotonin Transporter ( SERT) and the Norepinephrine Transporter ( NET). Clomipramine (parent drug) targets SERT, while its active metabolite targets NET, establishing a dual inhibitory profile that elevates the concentration of both Serotonin and Norepinephrine in the synaptic space. This acute molecular change is the initial step in a multi-week adaptive cascade that facilitates prolonged changes in neural signaling.

---

Non-Specific Receptor Blockade

In addition to reuptake inhibition, the drug acts as a strong antagonist at several non-monoamine targets, including Histamine H1 and Muscarinic Acetylcholine receptors. This inherent non-specificity results in the modulation of other central and peripheral systems. This engagement across multiple signaling pathways contributes to changes in autonomic and arousal responses, functionally expanding the drug's mechanistic scope beyond monoamine action.

Клофранил (Clomipramine Hydrochloride) is administered primarily through the oral route, available in multiple strengths of capsules and tablets. The general principles of its use focus on a controlled, gradual introduction to establish a sustained maintenance regimen.

Dosing and Titration

For adults, the starting dose is typically 25 mg taken once daily. The standard approach involves a gradual dose titration, increasing the daily amount over time to reach a maintenance range, commonly between 100 mg and 250 mg per day. The maximum recommended daily dose for adults is 250 mg.

Frequency and Special Conditions

The initial dosing may involve divided portions, but the maintenance dose is consolidated into a single daily dose administered at bedtime. It is also advised that the medicine be taken with food or immediately after a meal to aid proper intake. The contents of the capsule form may be mixed with soft food, such as applesauce, if needed, and swallowed without chewing.

Population Adjustments

Specific adjustments are utilized for certain patient populations. For older adults, treatment is initiated at a low dose (e.g., 10 mg daily), with a lower maximum maintenance range generally set between 30 mg and 75 mg per day. For pediatric patients (aged 10 and older), the maximum daily amount is capped at 200 mg or 3 mg per kilogram of body weight, whichever is less. The use protocol includes a long-term plan and a gradual dose reduction (tapering) upon discontinuing the medicine.

Research evidence / Overview of Studies for Клофранил

The clinical evaluation of Клофранил (Clomipramine) is documented through decades of official research, including numerous clinical trials, comparative studies, and meta-analyses. The focus of this research was observed in how symptoms evolved in specific patient groups under controlled conditions. The evidence base shows variability across indications, with some areas having more comprehensive trial data than others.

---

Evidence for Use in Obsessive-Compulsive Disorder (OCD)

Official research has focused on Клофранил in the context of Obsessive-Compulsive Disorder (OCD). Studies primarily consist of short-term Randomized Controlled Trials (RCTs) and multicenter, placebo-controlled trials. These trials were evaluated in both adults and pediatric groups (children and adolescents aged 10 and older). The research monitored outcomes related to symptom intensity and variability, using validated tools like the Yale-Brown Obsessive Compulsive Scale (YBOCS).

Follow-up research described patterns related to symptom recurrence and the state of patient measurements after the initial study period. Overall, the evidence contributes to the broader understanding of the patterns of symptom measurement in this specific patient population. What remains uncertain is the full extent of long-term outcomes for complete, sustained symptom remission, as this is not fully established in the literature.

---

Evidence for Use in Cataplexy Associated with Narcolepsy

The evidence for this use is limited to a foundation of Controlled Clinical Trials, open-label studies, and case series. These studies examined specific outcomes describing episodic or acute changes, focusing on the frequency and intensity of cataplexy attacks. Available trials reported measurements related to the frequency of attacks during defined study intervals.

However, the existing study base is characterized by older trials and the sample sizes were modest. Critically, the research focus is limited to cataplexy and does not determine whether an individual will experience similar measured changes regarding the core symptoms of narcolepsy, such as excessive daytime sleepiness.

---

What is Still Uncertain About Клофранил Research

Scientific literature documents several limitations and research gaps. Comparative evidence is lacking in contemporary, large-scale trials against current standard-of-care treatments for indications like Major Depressive Disorder. Evidence quality varies across studies, particularly for uses like chronic pain, where the primary outcome measurements were observed to vary. The research does not determine whether an individual will respond similarly, as findings describe group patterns, and subgroup findings for specific comorbidities are still emerging.

Key Studies & References Clomipramine - NIH NCBI Bookshelf Overview

Common questions about Клофранил (FAQ)

Q: Does this medication make you sleepy?

A: According to the official product information, somnolence (a technical term for sleepiness or drowsiness) is listed as a possible undesirable effect. Because of this potential effect, caution is generally advised when performing tasks that require alertness, such as driving or operating machinery.

Q: How should I store this medication?

A: The official labeling indicates that Клофранил is stored at controlled room temperature, typically between 20°C to 25°C. The labeling also indicates that protection from excessive moisture and light is necessary to maintain the medication’s quality.

Q: Can I take an alcoholic drink while using this medicine?

A: The regulatory documents mention that caution or avoidance regarding alcohol consumption is necessary while using this medication. This is due to the potential for alcohol to increase certain side effects, particularly CNS effects (effects on the central nervous system) such as drowsiness and dizziness.

Q: What should I do if I miss a dose?

A: The product information outlines the steps for a missed dose: it may be taken as soon as it is remembered. However, if it is nearly time for the next dose, the missed dose is typically skipped, and the regular schedule is continued. Taking two doses at once is not recommended by the official instructions.

Storage and Disposal of Clomipramine (Клофранил)

Storage of Clomipramine Hydrochloride must adhere strictly to regulatory conditions to maintain stability.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Environment	Protect from light and moisture. Do not freeze and store away from excess heat.
Packaging	Keep in the original container, which must be a tight, light-resistant container, and kept tightly closed
Child Safety	Keep out of the sight and reach of children due to the risk of serious accidental ingestion.

---

Disposal Instructions

Expired or unused Clomipramine must not be thrown away via wastewater or household waste. Disposal must follow local regulatory requirements for pharmaceutical take-back programs, as the product is documented as toxic to aquatic life.